Finance

Lists
VCEL:NASDAQ
Vericel Corp
$44.20
-0.76%
(-0.34) 1D
Aug 14, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for VCEL...
Open
$44.53
High
$44.55
Low
$43.65
Mkt. cap
2.26B
Avg. vol.
490.93K
Volume
0.00
P/E ratio
105.82
52-wk high
$49.32
52-wk low
$28.95
EPS
$0.42
Beta
1.07
Shares outstanding
51.21M
No. of employees
398
Open
$44.53
High
$44.55
Low
$43.65
Mkt. cap
2.26B
Avg. vol.
490.93K
Volume
0.00
P/E ratio
105.82
52-wk high
$49.32
52-wk low
$28.95
EPS
$0.42
Beta
1.07
Shares outstanding
51.21M
No. of employees
398
Profile
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan. In the spring of 2014, Aastrom Bio acquired Sanofi's cell therapy and regenerative medicine business which Sanofi had acquired when purchasing Genzyme in 2011. This transformed Aastrom in several ways: it increased the employee count by 8-fold and provided a revenue stream and products to market, which it had not had before. In October 2014, the company changed its name from Aastrom Bio to Vericel and relocated its headquarters from Ann Arbor, Michigan to Cambridge, Massachusetts. Wikipedia
About Vericel Corp
CEONick Colangelo
Employees398
Founded1989
HeadquartersCambridge, Massachusetts, United States
SectorBiotechnology
Websitevcel.com
Analyst ratings
Based on 4 analysts giving stock ratings to VCEL in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for VCEL in the last 3 months.
Highest
Current $44.20
$72.00 (+62.90%)
Average
$61.50 (+39.14%)
Lowest
$58.00 (+31.22%)
Analyst
Recommendation
Action
Price target
Projected
Date
Richard Newitter
Truist Financial
Buy
Reiterated
$58.00
+31.2%
07/31/2026
Swayampakula Ramakanth
H.C. Wainwright
Buy
Maintained
$72.00
+62.9%
07/31/2026
Josh Jennings
TD Cowen
Buy
Reiterated
$58.00
+31.2%
07/31/2026
Caitlin Roberts
Canaccord Genuity
Buy
Maintained
$58.00
+31.2%
06/24/2026
Ryan Zimmerman
BTIG
Hold
Maintained
-
-
04/05/2026
Unknown Analyst
Ladenburg Thalmann & Co.
Buy
Reiterated
$62.00
+40.3%
02/27/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
67.50M
92.92M
68.42M
77.46M
Cost of goods sold
17.92M
19.79M
19.16M
21.06M
Cost of revenue
17.92M
19.79M
19.16M
21.06M
Research and development expenses
6.32M
7.25M
8.10M
7.49M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
39.82M
43.46M
49.23M
48.48M
Operating expense
46.14M
50.71M
57.33M
55.97M
Total operating expenses
64.05M
70.50M
76.49M
77.02M
Operating income
3.45M
22.42M
-8.06M
434.00K
Other non operating income
-26.00K
-36.00K
71.00K
-22.00K
EBT including unusual items
5.07M
24.10M
-6.30M
2.21M
EBT excluding unusual items
5.07M
24.10M
-6.30M
2.21M
Income tax expense
-
859.00K
-
-
Effective tax rate
-
3.56%
-
-
Other operating expenses
-
-
-
-
Net income
5.07M
23.24M
-6.30M
2.21M
Net profit margin
7.52%
25.01%
-9.21%
2.85%
Earnings per share
0.10
0.45
-0.12
0.04
Interest and investment income
1.81M
1.88M
1.85M
1.95M
Interest expense
-158.00K
-162.00K
-160.00K
-160.00K
Net interest expenses
1.65M
1.72M
1.69M
1.79M
Depreciation and amortization charges
-
-
-
-
EBITDA
6.39M
25.50M
-4.80M
4.05M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps